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S100B belongs to a multigenic family of Ca
2+-binding proteins of the EF-hand type and is expressed in high abundance in
the brain. S100B interacts with target proteins within cells thereby altering their functions once secreted/released with the
multiligandreceptorRAGE.Asanintracellularregulator,S100Baﬀectsproteinphosphorylation,energymetabolism,thedynamics
of cytoskeleton constituents (and hence, of cell shape and migration), Ca
2+ homeostasis, and cell proliferation and diﬀerentiation.
As an extracellular signal, at low, physiological concentrations, S100B protects neurons against apoptosis, stimulates neurite
outgrowth and astrocyte proliferation, and negatively regulates astrocytic and microglial responses to neurotoxic agents, while
at high doses S100B causes neuronal death and exhibits properties of a damage-associated molecular pattern protein. S100B
also exerts eﬀects outside the brain; as an intracellular regulator, S100B inhibits the postinfarction hypertrophic response in
cardiomyocytes, while as an extracellular signal, (high) S100B causes cardiomyocyte death, activates endothelial cells, and
stimulates vascular smooth muscle cell proliferation.
1.Introduction
S100 is a multigenic family of small (∼10kDa) Ca2+-binding
proteins of the EF-hand type comprising 25 members
exclusively expressed in vertebrates [1, 2]. In humans, the
genes encoding S100A1-S100A16, S100A7L2, S100A7P1,
and S100A7P2 map to chromosome 1q21, and the genes
encoding S100A11P, S100B, S100G, S100P, and S100Z map
to chromosomes 7q22-q31, 21q22, Xp22, 4p16, and 5q13,
respectively [3]. With the exception of S100G which is
aC a 2+-modulator protein involved in the buﬀering of
cytosolic Ca2+, the members of this protein family are
Ca2+ sensor proteins which once activated by Ca2+ interact
with intracellular target proteins thereby regulating their
activities. However, S100A10 is a constitutively activated
protein involved in regulatory functions irrespective of the
cytosolic Ca2+ level. It should be pointed out that: (1) the
Ca2+-binding aﬃnity of S100 proteins (as measured in vitro)
is considerably lower than that of the universal, intracellular
Ca2+ sensor protein, calmodulin [4]; (2) however, S100’s
Ca2+-binding aﬃnity increases in the presence of target
proteins (5) and/or, for some S100 members, Zn2+ [5, 6];
and (3) Ca2+-independent interactions have been described
for certain S100 proteins [7]. Importantly, diﬀerently from
the ubiquitous calmodulin, individual S100 proteins exhibit
a cell-speciﬁc expression, and some S100 proteins exert both
intracellular and extracellular regulatory activities [1, 8].
Moreover, with the exception of S100G which is monomeric,
all other S100 proteins exist within cells as dimers (mostly
homodimers, and in certain cases heterodimers), and some
of the secreted/released S100 proteins form oligomers [1, 9,
10].
S100B was the ﬁrst member of the S100 protein family to
be identiﬁed. This protein is highly abundant in the brain
where it localizes to astrocytes (which represent the most
abundant source of S100B in absolute), although certain
neuronal populations also appear to express it [1, 10].
S100B is also expressed in cells outside the brain, such as
melanocytes, adipocytes, chondrocytes, Schwann cells, glial
cells of the gastrointestinal apparatus, supporting cells of the2 Cardiovascular Psychiatry and Neurology
adrenal medulla, dendritic cells, mature skeletal myoﬁbers,
skeletal muscle satellite cells, and arterial smooth muscle
cells [1, 10–12]. Cardiomyocytes do not express S100B, but
S100Bbecomesexpressedinthecardiomyocytessurvivingan
infarction under the action of catecholamines [13–15].
S100B is constitutively secreted by astrocytes and its
secretion can be regulated by a number of factors [10].
It is also secreted by adipocytes along with free fatty
acids under the action of catecholamines [16]. Moreover,
S100B is passively released from damaged and/or necrotic
cells. The presence of S100B in the cerebrospinal ﬂuid,
serum, and amniotic ﬂuid above threshold levels is used for
diagnostic/prognostic purposes [17].
S100B exerts regulatory activities within cells and, once
secreted/released, it acts as an extracellular signal. However,
accumulating evidence suggests that intracellular regulatory
activities of S100B diﬀer substantially from its extracellular
eﬀects; that is, no unitary theory of intracellular and
extracellular S100B’s eﬀects can be envisaged at present.
2.IntracellularS100B
As an intracellular regulator, S100B has been impli-
cated in the regulation of protein phosphorylation, energy
metabolism, the dynamics of cytoskeleton constituents (and
hence, of cell shape and migration), Ca2+ homeostasis, and
cell proliferation and diﬀerentiation [10]. The large variety
of cell activities regulated by S100B can be explained by
the high abundance of the protein in S100B-expressing
cells and its cytoplasmic localization. Thus, the enhanced
expression of S100B in melanoma cells has been suggested to
becausallyrelatedtotumorprogressiongiventhatS100Bnot
only interacts with the tumor suppressor, p53, blocking its
phosphorylation [18] but also downregulates p53 expression
(with p53 in turn downregulating S100B expression) [19],
and pharmacological blockade of S100B activity with pen-
tamidine, a drug that disrupts S100B-p53 interactions [20],
results in a signiﬁcant tumor growth inhibition [21]. How-
ever, interaction with and/or downregulation of p53 might
not be the sole mechanism whereby intracellular S100B
stimulates cell proliferation. Indeed, intracellular S100B has
been shown to stimulate proliferation and modulate cell
diﬀerentiation via activation of PI3K and its downstream
signaling pathways in neuronal and astrocytic cell lines
[22, 23] and to modulate cell diﬀerentiation via activation
of IKKβ/NF-κB in myoblast cell lines [12], and its induc-
tion by the so-called SOX trio in chondroblasts has been
causally related to inhibition of chondrocyte diﬀerentiation
[14]. Moreover, S100B positively regulates migration in
astrocytes via activation of a Src/PI3K/RhoA/ROCK module
[23]. Thus, intracellular S100B might serve the function
of negatively regulating cell diﬀerentiation and stimulating
proliferation and migration in cell lines. Whether S100B
serves these functions during development and tissue regen-
erationremainstobeestablished.AtightregulationofS100B
expression appears to take place during neurogenesis, with
relatively high S100B expression levels in neural progenitor
cells as long as they are proliferating and migrating, followed
by repression of S100B expression in coincidence with
glial precursor cell diﬀerentiation and resumption of S100B
expression in diﬀerentiated astrocytes [23, 24]. Interestingly,
S100B appears to be required for MIO-M1 cells, a human
M¨ uller glia cell line, to form neurospheres (i.e., spherical
aggregates of highly proliferating, round cells characterized
by low adhesiveness to the substrate and the expression
of transcription factors characteristic of neural stem cells
[25]) [23]. Indeed, S100B knockdown in these cells has
been shown to result in reduced neurosphere formation
and proliferation and acquisition of an astroglial phenotype
(unpublished results). Also, rat primary astrocytes tran-
siently downregulate S100B expression when exposed to
the diﬀerentiating agent, db-cAMP, and reexpress S100B at
later stages of db-cAMP-induced diﬀerentiation [23]. In this
case, as well as in the case of glioma cell lines induced
to acquire a diﬀerentiated phenotype by serum starvation,
reexpressed S100B ﬁrstly appears to be located at the origin
of cell extensions in proximity of F-actin bundles [23].
These results are compatible with the possibility that: (1)
S100B is required for neural progenitor cells to maintain
stemness and migratory capacity; (2) transient repression of
S100Bexpressionisfunctionallyassociatedwithearlystepsof
astrocyticdiﬀerentiation;(3)persistenceofS100Bexpression
in neural progenitor cells might result in disturbances in
neural cell diﬀerentiation [26, 27]; and (4) reexpression
of S100B in diﬀerentiated astrocytes might be functionally
linked to the maintenance of astrocytic processes as well as
other cell activities (see above). The molecular mechanism
regulating S100B expression in astrocytes depending on the
developmental stage remains to be identiﬁed; preliminary
evidence suggests that EGF signaling might cause downregu-
lation of S100B expression in diﬀerentiating astrocytes [24].
Characteristically,S100Bexpressionisenhancedinastroglio-
sis, a process consisting of proliferation and activation of
astrocytes followed by their hypertrophy as observed after
a brain insult that compromises brain tissue integrity or
during chronic brain inﬂammatory states [28]. This raises
the possibility that S100B might contribute to astrocyte
reactivity following brain damage by favoring both the
migration of activated astrocytes to the site(s) of damage and
the formation and/or stabilization of F-actin cytoskeleton
in astrocytic processes, likely via a Src/PI3K/RhoA/ROCK
pathway and a Src/PI3K/Akt/GSK3β/Rac1 pathway [23],
and possibly by regulating as yet unidentiﬁed intracellular
activities via the Src/PI3K module. PI3K is known to
play a regulatory role in inﬂammatory cells [29, 30], and
astrocytes are active players in innate immunity in the
brain [31]. Indeed, there is evidence that PI3K signaling
might play an important role in both astrogliogenesis
[32] and astrocytic activation in neuroinﬂammation [33–
36]. Experimental evidence suggests that administration of
arundic acid (ONO-2506), an agent suggested to inhibit
S100B synthesis [37], in a rodent ischemia model results
in inhibition of overexpression of S100B in astrocytes and
the subsequent activation of signaling pathways in the peri-
infarct area, in a reduction of delayed infarct expansion
and in amelioration of neurologic deﬁcits [38]. Conversely,
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transgenic (TG) mice, infarct volumes are signiﬁcantly
increased during the ﬁrst postinfarct days and astrogliosis
is enhanced compared with controls [39]. Moreover, S100B
TG mice show increased susceptibility to perinatal hypoxia-
ischemia [40], and overexpression of S100B has been shown
toaccelerateAlzheimerdisease-likepathologywithenhanced
astrogliosis and microgliosis [41]. In this regard, association
between elevated brain levels of S100B and several brain
pathologies including Alzheimer disease is a well-established
notion [10, 42]. Although in the aforementioned cases [38–
41]i ti sd i ﬃcult to distinguish between intracellular and
extracellular eﬀects of S100B, it is tempting to speculate that
elevated levels of intracellular S100B might contribute to
astrocyteactivationduringthecourseofbraindamageandto
astrogliosis. Yet, these putative eﬀects of intracellular S100B
appear to be counterbalanced by S100B extracellular eﬀects
in part (see below).
As mentioned earlier, cardiomyocytes do not express
S100B in normal physiological conditions; however, S100B
becomesexpressedincardiomyocytessurvivinganinfarction
under the action of catecholamines and acts to inhibit the
cardiomyocytehypertrophicresponsewithamechanismthat
remains to be elucidated [13–15].
Genetic evidence has been presented that S100B exerts
inhibitory eﬀects on caﬀeine-induced rises in the free Ca2+
concentration in astrocytes, suggesting that S100B might
act to reduce cytosolic Ca2+ concentration [43]. However,
the molecular mechanism underlying this S100B eﬀect has
not been identiﬁed. On the other hand, acute infusion
of S100B knockout (KO) mice with norepinephrine (NE)
after a 28-day treatment with NE results in a signiﬁcantly
smaller increase in mean arterial pressure (MAP) compared
to wild-type (WT) and S100B TG mice, with a tendency
of S100B TG mice to respond with higher MAP values
compared with WT mice [11]. Arterial smooth muscle cells
(ASMCs) from S100B KO mice are less responsive to NE
treatment compared with WT ASMCs due to either reduced
Ca2+ mobilization from internal Ca2+ stores or reduced
extracellular Ca2+ inﬂux [11], pointing to a requirement
of S100B for appropriate Ca2+ responses to NE. However,
this does not apply to cardiomyocytes from S100B KO
mice pointing to a dissociation between eﬀects of S100B in
cardiomyocytes and those in ASMCs in the same experimen-
tal setting (i.e., stimulation with NE) [11]. The molecular
mechanism underlying S100B’s ability to enhance cytosolic
Ca2+ concentration in ASMCs also remains to be identiﬁed.
The giant phosphoprotein AHNAK, which modulates L-
type Ca2+ channels in response to β-adrenergic stimulation
[44], interacts with phospholipase Cγand PKC-αincreasing
intracellular Ca2+ mobilization [45] and is expressed in
smooth muscle cells and cardiomyocytes [46], is an S100B
targetprotein[47].Thus,AHNAKisapotentialintermediate
linking S100B to elevation of cytosolic Ca2+ levels [11].
However, additional intermediates appear to come into
play because S100B-AHNAK interactions also occur in
cardiomyocytes which do not require S100B for increasing
cytosolic Ca2+ levels in response to NE, as mentioned earlier.
Together, these results point to a diﬀerential ability of
S100B to intervene in the regulation of the cytosolic Ca2+
concentration in activated cells depending on the cell type,
suggesting that cell-speciﬁc intermediates might link S100B
to regulators of cytosolic Ca2+ levels.
3.ExtracellularS100B
3.1.S100BActsasanExtracellularSignalinBrain,Vasculature
and Heart. The ﬁrst evidence for the presence of S100B
outside neural cells was provided by Michetti et al. [48]w h o
detected measurable amounts of S100B in the cerebrospinal
ﬂuid of patients with multiple sclerosis. S100B was ever
since taken as a marker of brain disease [17]. Subsequently,
Shashoua et al. detected S100B in the brain extracellular
ﬂuid [49], and later on, Van Eldik and Zimmer [50]
demonstratedthatanastrocytecelllinesecretedS100Bunder
conventional culture conditions. Secretion of S100B from
astrocytes, which occurs via a noncanonical secretion route,
was subsequently shown to be regulated by a number of
factors/conditions, of which some enhance secretion (e.g.,
serotonin, lysophosphatidic acid, low levels of glutamate,
forskolin, low extracellular Ca2+ and/or K+ levels, TNF-α,
IL-1β, metabolic stress, serum deprivation, kainic acid, the
neurotoxin 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine,
natural antioxidants, and antipsychotic drugs) while some
other reduce secretion (e.g., high levels of glutamate, glucose
and K+, inhibition of Src kinase activity, cell conﬂuence,
Ca2+ channel blockers and gap junction inhibitors) [10,
51–53]. However, a rather small fraction of intracellular
S100B is being secreted constitutively by astrocytes, and
S100B secretagogues cause a 2-4-fold increase in secretion at
most [10]. Given that the total brain S100B concentration
amounts to 10–20μM; that the brain intercellular space
is relatively narrow; and that a fraction of secreted S100B
diﬀuses into the cerebrospinal ﬂuid, the brain extracellular
S100B concentration should amount to a few nM under
normal physiological conditions. Yet, the brain S100B con-
centrationoutsidecellsmightbeseveralordershigherincase
of astrocyte damage and/or necrosis due to a combination of
passivereleaseoftheintracellularprotein,defectiveclearance
of the extracellular protein in consequence of inﬂammation,
and/or Ca2+-induced formation of S100B oligomers [54, 55]
and adhesion of S100B oligomers to the extracellular matrix.
The existence of an extracellular fraction of S100B was
soon put in relation to eﬀects of the protein on brain cells
inasmuchasaneuriteextensionfactorfrombovinebrainwas
identiﬁed as a disulﬁde-linked dimer of S100B [56]. Whereas
earlyreportsonextracellularS100Bsupportedthepossibility
that the protein might function as a trophic factor towards
neurons and astrocytes [10], the observation that elevated
levels of S100B were present in the temporal lobe of patients
with Alzheimer disease in conjunction with the presence
of highly reactive S100B-positive astrocytes surrounding
the neuritic plaques [57] raised the possibility that S100B
might contribute to Alzheimer disease neuropathology.
Thus, research on extracellular S100B proceeded ever since
along two main directions, on the basis of the protein’s dual
roleasaneurotrophicfactorandasaneurotoxicfactor.These
apparently contradictory eﬀects of S100B in the brain were4 Cardiovascular Psychiatry and Neurology
S100B
(low)
Astrocyte
Neuron survival,
neurite outgrowth
(a)
S100B
(high)
S100B
(high)
IL-6
TNF-α
NO
IL-1β
TNF-α
NO
TNF-α
Microglia
activation
Neuron
ROS production,
death
Astrocyte
(b)
S100B
(high) IL-6
MCP-1
VSMC proliferation
(c)
S100B
(high)
Cardiomyocyte death
(d)
Figure 1: Schematic representation of extracellular eﬀects of S100B in brain, heart, and vasculature. (a) At low concentrations, S100B
promotes neuronal survival and stimulates neurite outgrowth via stimulation of RAGE signaling. (b) At high concentrations, S100B causes
neuronal death both directly via excessive stimulation of RAGE signaling in neurons and indirectly via RAGE-dependent activation of
microglia and astrocytes. (c) At high concentrations, S100B stimulates VSMC proliferation via RAGE activation. See text for details. (d)
S100B released from necrotic cardiomyocytes kills nearby, surviving cardiomyocytes via RAGE activation.
shown to be dependent on the protein’s concentration, with
doses of S100B up to a few hundred nM being neurotrophic
and higher doses being neurotoxic [42]. Indeed, S100B at
high doses causes neuronal apoptosis both via a direct action
on neurons [58] and via stimulation of nitric oxide (NO)
release by astrocytes [59]( Figure 1(a)). Moreover, at high
doses, and in the presence of cofactors (either bacterial
endotoxin or interferon-γ [IFN-γ]), S100B enhances NO
release by microglia [60, 61], the brain resident macrophages
(Figure 1(b)). The ﬁnding that S100B can activate microglia,
albeit at high doses, suggests that the protein might have
a role in neuroinﬂammation, a possibility substantiated by
other studies of eﬀects of S100B on microglia and astrocytes
[62–66]( Figure 1(b)).
A strong impulse to research on extracellular eﬀects of
S100B in the brain came from the observation that RAGE
(receptor for advanced glycation end products), a multili-
gand receptor of the immunoglobulin superfamily expressed
in several cell types including neurons during development
as well as in activated inﬂammatory cells, transduces S100B’s
eﬀects on endothelial cells and microglia [67]. Indeed,
RAGE ligation by S100B on neurons has been shown to
be responsible for both the protein’s neurotrophic eﬀects
(at low S100B doses) via activation of a Ras/MEK/ERK/NF-
κB/Bcl-2 pathway and a Ras/Cdc42-Rac1 pathway, and pro-
apoptoticeﬀects(athighS100Bdoses) viahyperactivationof
the Ras/MEK/ERK pathway and consequent overproduction
of reactive oxygen species (ROS) [68]( Figure 1(b)). These
latter results anticipated that: (1) extracellular S100B might
aﬀect any RAGE expressing cell; (2) the outcome of S100B
action might be dependent on RAGE functionality and/or
concentration; (3) the diﬀerent outcome of S100B eﬀects
depending on the protein’s concentration might be depen-
dent on the number of RAGE molecules engaged on the
cell surface and/or the physical state of S100B; and (4) the
relatively high doses of S100B required for RAGE-dependent
activation of inﬂammatory cells, compared with absence of
eﬀects at low doses, might reﬂect a diﬀerential ability of
RAGE to recruit diﬀerent intermediates linking the receptor
to intracellular signaling pathways depending on the cell
type, RAGE’s physical state and/or the intensity/duration of
RAGE stimulation.Cardiovascular Psychiatry and Neurology 5
As to point (1), S100B has been indeed used ever
since as a generic RAGE agonist [8, 10]. However, RAGE-
independent eﬀects of low and high doses of S100B
have been documented in the case of cultured myoblasts
(which express RAGE) in diﬀerentiation medium [69–
71], which raises the possibility that extracellular factors
might regulate S100B/RAGE interactions. Indeed, recent
evidence suggests that in high-density myoblast cultures
S100B (up to 1nM) induces the formation of a multi-
meric RAGE/S100B/bFGF/FGFR1 transcomplex in which
bFGF/FGFR1 antimyogenic signaling is enhanced while
RAGE promyogenic signaling is inhibited, as opposed to
RAGE-dependent regulatory eﬀects of S100B in low-density
myoblast cultures (a condition in which S100B does not bind
to bFGF/FGFR1 and thus fully activates RAGE) (F. Riuzzi, G.
Sorci and R. Donato, submitted for publication).
As to point (2), in general no eﬀects of S100B could
be detected in neurons, astrocytes, and inﬂammatory cells
that had been transfected with a dominant negative RAGE
mutant (i.e., RAGE lacking the cytoplasmic and transducing
domain) or in which RAGE expression had been knocked
down (11). However, S100B has been shown to stimulate
NO release from IFN-γ-treated microglia to the same
extent in microglia that had been stably transfected with
either full-length RAGE or dominant negative RAGE, but
to a signiﬁcantly larger extent in these cases compared
with mock-transfected microglia [72]. This suggests that
at least in the case of S100B-induced NO release by
microglia, the RAGE extracellular domain might serve to
concentrate S100B on the microglial cell surface thereby
allowing S100B to potentiate IFN-γ eﬀect. Whether S100B
interacts with IFN-γ thereby potentiating IFN-γ eﬀects
remains to be established. Yet, at high doses S100B causes
overproduction of ROS via activation of the NADPH
oxidase complex in monocytes/macrophages in the absence
of co-factors, with ROS in turn, activating Src tyrosine
kinase which recruits a Ras/MEK/ERK1/2/NF-κBp a t h w a y
and a Rac1/Cdc42/MKK6/p38 MAPK/NF-κBp a t h w a yw i t h
ensuing upregulation of IL-1β,T N F - α, COX-2 and iNOS
expression [73, 74]. In these latter works, RAGE-signaling
has been proposed, but not directly demonstrated to have
a role in S100B eﬀects. By contrast, at high doses S100B
causes myoblast death via ROS overproduction, via a RAGE-
independent mechanism that remains to be elucidated [70].
Ontheotherhand,S100B/RAGEsignaling-dependentRAGE
induction and activation in neuronal cells might contribute
to the protective eﬀect of low S100B doses towards β-
amyloid neurotoxicity and to ampliﬁcation of β-amyloid
neurotoxicity by high S100B doses [75].
As to point (3), preliminary evidence suggests that at
high, but not low doses S100B chemoattracts microglia in
a RAGE-dependent manner; however at low doses the pro-
tein does chemoattract RAGE-overexpressing microglia (R.
Bianchi, Eirini Kastrisianaki, I. Giambanco, and R. Donato,
submitted for publication). This suggests the possibility
that at the levels found in normal physiological conditions
brain extracellular S100B cannot aﬀect microglia migration
due to the very low, if any expression levels of RAGE in
“resting” microglia, but the protein might contribute to
chemoattract microglia at the beginning of a brain insult
as a result of activation of microglia, a condition which
is accompanied by induction of RAGE in these cells [76].
Thus, increasing the density of RAGE molecules on the
microglial cell surface might cause S100B to switch from
a neurotrophic factor to a proinﬂammatory factor. In this
regard, it is known that RAGE is induced in a variety of cell
types by RAGE-activating ligands [77, 78]. Moreover, recent
evidence suggests that extracellular S100B exists in the form
of octamers and higher-order multimers in the nonreducing,
high Ca2+ conditions found in the extracellular ﬂuid; that
RAGE exists in the form of oligomers on the cell surface;
and that ligand-induced oligomerization is required for
RAGE to signal adequately [54, 55, 79]. Thus, the neurotoxic
and proinﬂammatory eﬀects of S100B might require the
occurrence of high levels of S100B oligomers/multimers
interactingwithRAGEoligomers(and/orcausing/enhancing
RAGEoligomerization).Importantly,dosesofS100Bcausing
neuronal apoptosis do not cause microglial apoptosis, a dif-
ference which is likely to depend on the diﬀerent scavenging
ability of neurons and microglia towards oxidants. Microglia
activation and chemotaxis are being usually considered in
the context of neuroinﬂammation. However, it should be
pointedoutthatmicrogliachemoattractionisnotnecessarily
a dangerous and/or inﬂammation-related event; “resting”
microglia are not exactly resting, microglia continuously
patrolling the territory, exerting a protective action by
virtue of their ability to keep the neuronal and astrocytic
extracellular milieu clean, and likely resolving mild degree
brain insults [80, 81]. According to these views microglia
are active players in brain tissue homeostasis under normal
physiological conditions, and thus (low) S100B’s ability to
chemoattract microglia might be beneﬁcial in case of mild
degree brain insults. However, whereas there is information
about the increased susceptibility to perinatal hypoxia-
ischemia and accelerated Alzheimer disease-like pathology
with enhanced astrogliosis and microgliosis in a background
of overexpressed S100B [82, 83], no information is available
inabackgroundofdeletionoftheS100Bgene.Thus,whether
or not is there any role of S100B in microglia-mediated
brain tissue homeostasis in normal physiological conditions
remains to be established.
As to point (4), RAGE engagement has been shown
to result in the activation of several downstream sig-
naling pathways [77, 78]. However, there appears to be
no univocal set of signaling pathways that are being
activated by RAGE in diﬀerent cell types. For example,
whereas the Ras/MEK/ERK1/2/NF-κB pathway plays a major
role in (low) S100B/RAGE-induced neuronal survival (via
upregulation of the antiapoptotic factor, Bcl-2) and (high)
S100B/RAGE-induced neuronal death (via overproduction
of ROS) [68], its activation is not critical for (high)
S100B to upregulate the expression of the proinﬂamma-
tory enzyme, COX-2, in microglia, S100B/RAGE activating
a Cdc42/Rac1/JNK/AP-1 pathway and a Ras/Rac1/NF-κB
pathway in this latter case [64, 66]. Yet, the MEK/ERK1/2
pathway does mediate the S100B/RAGE-induced upregu-
lation of IL-1β and TNF-α expression and secretion by
microglia [84]. Incidentally, at low doses S100B does not6 Cardiovascular Psychiatry and Neurology
activate microglia [60, 61], albeit synergizing with IL-1β
and TNF-α to upregulate COX-2 expression [66]; instead,
low S100B blocks trimethyltin-induced increase in TNF-
α expression in microglia (via a mechanism that remains
to be identiﬁed) [85]. Also, whereas high S100B has
been shown to activate a RAGE/ROS/PI3K/Akt/NADPH
oxidase/ROS pathway leading to lipid peroxidation and
caspase-3 activation that cause dorsal root ganglia neuron
apoptosis [86], the PI3K/Akt module does not appear to
haveanyroleinS100B/RAGE-inducedupregulationofCOX-
2 expression in microglia [66] .M o r e o v e r ,h i g hl e v e l so f
S100B cause GSK3β-dependent hyperphosphorylation of
τ protein (a hallmark of Alzheimer disease) via RAGE-
dependent activation of JNK and upregulation of Dickopﬀ-
1 ,as t i m u l a t o ro fG S K 3 β activity, in human neural stem
cells [87]. So far, intermediates linking S100B/RAGE to
signaling pathways include Src [88, 89] and diaphanous-1
[90]. It is tempting to speculate that the amount of RAGE
expressed on the cell surface (which should condition the
extent of RAGE oligomerization) and the relative fractions of
octameric and multimeric S100B outside the cell might play
a role in the choice between the intermediates recruited to
RAGE, not to mention the potential recruitment to RAGE of
other, cell-speciﬁc intermediates, possible crosstalks among
intracellular signaling pathways, and autocrine/paracrine
eﬀects of factors released by the aﬀected cells in consequence
of the S100B/RAGE interaction.
Interestingly, levels of brain S100B in epileptic patients
areincreasedcomparedwithcontrols[91],andS100Brelease
is increased in a mouse model of epilepsy [92]. In this latter
experimental setting, the amplitude of hippocampal kainic
acid-induced gamma oscillations is signiﬁcantly reduced
compared with WT mice, and released S100B enhances
hippocampal kainic acid-induced gamma oscillations, an
event that is abrogated by the local infusion of either an
S100B neutralizing or a RAGE-neutralizing antibody [92].
Thus, S100B-activated RAGE signaling appears to make
neurons more sensitive to the epileptogenic activity of
kainic acid. Although no information is available about
the cellular localization of RAGE in these studies, it is
possible that S100B hyperpolarizes inhibitory interneurons
in the hippocampus via RAGE engagement thereby caus-
ing dysinhibition of pyramidal neurons and enhancing
their sensitivity to kainic acid. Indeed, some evidence
suggests that S100B aﬀects neuronal electrical discharge
activity by modulation of potassium currents at low doses
[93].
A role for S100B has been suggested in the pathogenesis
and/or pathophysiology of schizophrenia based on the
observation that serum levels of the protein are increased
in this psychiatric disorder [94–96]. However, whereas in
early studies the increased levels of S100B in patients
with schizophrenia have been reported to occur without
an indication for signiﬁcant glial or neuronal damage,
a ﬁnding that has been interpreted as an indirect evi-
dence for increased active secretion of S100B by astrocytes
during acute psychosis [97], other studies have shown
that astrocyte and/or oligodendrocyte activation occurs in
schizophrenic patients [98, 99]. Whereas alterations in glial
and/or serum S100B levels may be indicative of participation
of glial cells in the pathophysiology of schizophrenia, it
is not known whether the increased serum S100B levels
are indicative of the participation of the protein in the
pathogenesis/pathophysiology of schizophrenia and what
the role of (intracellular and/or extracellular) S100B in
this psychiatric disorder might be. Recent work has shown
that serum S100B levels normalize while levels of sRAGE
(i.e., a product of digestion of RAGE acting as a scavenger
of RAGE ligands) increase under antipsychotic treatment
[100],suggestingthatantipsychoticdrugsmightenhancethe
secretion/activity of matrix-metalloproteinases responsible
for sRAGE production. Given the established role of RAGE
in inﬂammation and of sRAGE as a protective factor against
a number of inﬂammatory diseases [77, 78], and since
a neuroinﬂammatory component characterizes psychotic
states[101–103],onemayhypothesizethatduringthecourse
of acute schizophrenia activated astrocytes release more
S100B either to aid in protecting neurons or to amplify neu-
roinﬂammation; the concomitant liberation of sRAGE from
inﬂammatory cells (e.g., activated astrocytes and microglia)
might then act to reduce the activity of RAGE ligands
such as S100B, so as to extinguish/reduce the inﬂammatory
response. However, this simpliﬁed model does not take into
account the role of conventional cytokines and chemokines
coming into play in the context of neuroinﬂammation and
schizophrenia. In addition, enhancement of S100B release
fromastrocytesmightnotbecausativeofpsychoticstatesper
se because schizophrenia does not necessarily occur in Down
syndrome (which is characterized by chronically elevated
S100B levels (see [104, 105])), in aged people (who also
show elevated S100B levels (see [106])), or in a variety of
neuroinﬂammatory states characterized by elevated S100B
levels [17]. Moreover, recent work raises the possibility that
release of S100B from adipocytes contributes signiﬁcantly
to the elevated serum S100B levels found in schizophrenia
[107, 108]. Although there is suggestion that variants
within the S100B gene predispose to a psychotic subtype
of bipolar aﬀective disorder, possibly via alteration of gene
expression [109–111],conclusions abouttheroleofS100B in
the pathogenesis/pathophysiology of schizophrenia should
await more detailed analyses. The recent identiﬁcation of
S100B as a novel dyslexia candidate gene along with three
other genes (i.e., PCNT, DIP2A,a n dPRMT2) mapping
to chromosome region 21q22.3 suggests that decreases
in S100B expression might contribute to certain dyslexia
phenotypes [112]. This preliminary observation, however,
lends support to the notion that alterations in S100B
expression may have profound eﬀects on brain functions
and represents a further stimulus towards the elucidation of
the functional role(s) of S100B at the cellular and molecular
level.
Regulatory eﬀects of extracellular S100B are not
restricted to the brain. Aside from eﬀects on monocytes/
macrophages, neutrophils, myoblasts, and lens epithelial
cells, S100B also exerts eﬀects on vascular endothelial
cells, vascular smooth muscle cells (VSMCs) (for review
see [10]), and cardiomyocytes (see below). In fact, S100B
engages RAGE in endothelial cells thereby activating NF-κBCardiovascular Psychiatry and Neurology 7
transcriptional activity, increasing expression of vascular cell
adhesion molecule-1, inducing monocyte chemoattractant
protein-1 and RAGE transcripts and abrogating sodium
nitroprusside-potentiated vasodilatation in response to ACh
in endothelial dysfunction in type II diabetic (Leprdb)
mice. Also, S100B enhances the interaction of RAGE with
the leukocyte β2-integrin Mac-1, thus increasing leukocyte
adhesion to endothelial cells. RAGE engagement by S100B
causes VSMC proliferation (thus impacting on the patho-
genesis of atherosclerosis) (Figure 1(c)) via stimulation of
NADPH oxidase, increased ROS generation, and activation
ofphospholipase D2andjanuskinase (JAK)2tyrosinephos-
phorylation, these eﬀects being enhanced in the presence
of high glucose concentrations or angiotensin II. Moreover,
S100B/RAGE interactions in VSMCs result in recruitment of
the nonreceptor Src tyrosine kinase and PKC and phospho-
rylation of caveolin-1, a component of caveolae, which are
stable membrane domains that are kept in place by the actin
cytoskeleton and act as multifunctional organelles. Eﬀects of
S100B/RAGE on VSMCs and stimulation of VSMC migra-
tion and release of IL-6 (Figure 1(c)), require p38 MAPK,
ERK1/2, NF-κB and STAT3 activities, and ROS production.
Recent evidence suggests that at concentrations >50nM
S100B induces cardiomyocyte apoptosis (Figure 1(d))v i a
RAGE-dependent phosphorylation of ERK1/2 and p53,
increased expression and activity of proapoptotic caspase-
3, and decreased expression of antiapoptotic Bcl-2 [113],
another example of dissociation between intracellular and
extracellular S100B eﬀects.
3.2. Extracellular S100B: Just a DAMP Protein? Most of
the results commented on thus far point to S100B as to
a damage-associated molecular pattern (DAMP) protein
that is, a factor released from damaged/necrotic cells and
endowed with the ability to activate cells of the innate
immune response, alter the function of cell types (such as
astrocytes, endothelial cells, and VSMCs) that participate
in the inﬂammatory response, and/or cause cell death.
In this regard, serum and cerebrospinal ﬂuid levels of
S100B are of diagnostic and/or prognostic value [17].
Compelling evidence suggests that extracellular S100B can
be considered as a DAMP factor in the context of accu-
mulation of the protein in the extracellular space: in this
case, S100B might contribute twice to the inﬂammatory
response, as a RAGE-activating ligand and as a factor capable
of upregulating RAGE expression in reactive cells. Thus,
S100B would contribute signiﬁcantly to propagation of
inﬂammation, and S100B-blocking agents might thus prove
beneﬁcial, attenuating inﬂammation and consequent cell
damage.
However, diﬀerently from S100A8, S100A9, and
S100A12, which are secreted by activated macrophages/
neutrophils in response to inﬂammatory stimuli [114, 115],
S100B is constitutively secreted by astrocytes in normal
physiological conditions [49–53], and serum levels of S100B
are relatively high at birth and in otherwise normal infants
decreasing to picomolar levels around puberty [116]. Also,
astrocytes might not be the sole source of serum S100B in
normal and pathological conditions [49, 107, 108]. These
observations suggest that the S100B’s function outside
the cell might go beyond its role as a DAMP protein
and/or that DAMP proteins may also play a role in tissue
development and/or regeneration. As mentioned earlier,
at low doses, S100B protects neurons against apoptotic
stimuli [68, 75, 117–119], enhances neurite outgrowth
[120–125], and stimulates astrocyte proliferation [126],
and the intraventricular infusion of low doses of S100B
induces neurogenesis within the hippocampus, which is
associated with an enhancement of cognitive functions
following experimental traumatic brain injury [127, 128].
Also, the protein is released by in vitro trauma and reduces
delayed neuronal injury [129–131]. The S100B protective
eﬀect towards neurons may also be indirect, the protein-
stimulating uptake of the neurotoxic glutamate by astrocytes
[132], reducing neurotoxin-dependent activation of
microglia and astrocyte [85], protecting neurons against β-
amyloid neurotoxicity [75] and reducing neuronal and glial
cytotoxicity under hypothermic conditions [133]. Moreover,
it has been suggested that the proliferation of neuronal
precursors in the adult brain reported to occur following
chronic treatment with antidepressants might be dependent
on upregulation of S100B expression in astrocytes and RAGE
expression in proliferating neuroblasts [134] although a
causal relationship between upregulation of astrocytic S100B
a n dn e u r o n a lR A G Ei nc o n s e q u e n c eo ft r e a t m e n tw i t h
antidepressants and proliferation of neuronal precursors has
not been established. Furthermore, extracellular regulatory
eﬀects of S100B might not be restricted to the brain,
vasculature and heart, nor might they be dependent on
RAGE exclusively. For example, nanomolar S100B stimulates
myoblast proliferation, thus potentially contributing to the
expansion of the myoblast population [71], a critical event
during muscle development and regeneration [135]. It is
intriguing, however, that RAGE and certain RAGE ligands
including S100B might play important roles in such diverse
contexts as the innate immune response on one side (see
above) and tissue development and regeneration on the
other side [8, 10, 68, 77, 78, 136–139]. Comparative analyses
of wild-type, S100B KO, S100B TG, and RAGE KO mice
might shed light in this regard.
Learning and memory processes long represent another
ﬁeld of action of extracellular S100B (for review see Refs. [1,
10, 140]). Indeed, S100B KO mice exhibit enhanced spatial
and fear memories and enhanced long-term potentiation
(LTP) in the hippocampal CA1 region, and perfusion of
hippocampal slices with S100B reverses the levels of LTP
to those of the wild-type slices [141]. This suggests that at
physiological levels, extracellular S100B might play a role
as a regulator of synaptic plasticity, although the molecular
mechanism underlying this activity remains to be elucidated.
Recently, hyperactivity and increased sensitivity to auditory
stimuli have been reported in RAGE KO mice, with no sig-
niﬁcant diﬀerences between KO and wild types in behavioral
tests for spatial memory and anxiety, though [142]. This
preliminary evidence suggests that S100B/RAGE interactions
might not be important for normal motor activity or spatial
and fear memories, although deﬁnite conclusions should
await analyses of double S100B-RAGE KO mice.8 Cardiovascular Psychiatry and Neurology
4. Conclusions
During the last two decades, the interest in S100B protein
function in the brain and the cardiovascular apparatus has
increased remarkably, mostly in view of its extracellular
eﬀects. By a combination of structural and functional
studies, the emerging picture is one in which extracellular
S100B exerts trophic and toxic eﬀects depending on the
concentration attained locally and the density of RAGE
molecules expressed on the surface of responsive cells.
Speciﬁcally, at low (i.e., nanomolar) S100B concentrations
and in the presence of a relatively low RAGE cellular
density, the protein might exert trophic eﬀects, whereas
at high (i.e., submicromolar-micromolar) and/or in the
presence of a relatively high RAGE cellular density, the
protein might be toxic, participating in the inﬂammatory
response and causing cell death. In general, S100B behaves
like a DAMP factor in a background of chronically elevated
extracellular concentrations, like those occurring in Down
syndrome, Alzheimer-like dementia, chronic neuroinﬂam-
mation, atherosclerosis, and probably schizophrenia as well
aswheneverRAGEisfoundonthecellsurfaceaboveacertain
threshold of density. Thus, extracellular S100B eﬀects appear
to be context-dependent. However, S100B’s trophic/toxic
eﬀects might not be necessarily transduced by RAGE [69–
72, 119].
The great deal of information presented on regulatory
eﬀects of extracellular S100B has somewhat obscured the
protein’sintracellularfunction(s).Thechangesintheexpres-
sion levels of S100B during certain phases of neural cell
development in vivo and in vitro [22, 24], the enhanced
S100B expression in reactive astrocytes (astrogliosis) [57]
and gliomas (as well as in several nonnervous tumor
cells) [4–6] and the involvement of intracellular S100B in
cell proliferation and diﬀerentiation [12, 21–23]c a l lf o r
a detailed analysis of the regulation of S100B expression
at the transcriptional and posttranscriptional level and of
physiologically relevant interactions of S100B within cells.
The importance of this issue is highlighted by the fact
that: (1) the amount of released S100B generally is a small
fraction of the protein’s intracellular content (thus, the
greater the content the larger the released fraction especially
in the case of S100B leakage from damaged/necrotic cells);
(2) within certain limits, intracellular regulatory eﬀects
are proportional to the S100B concentration within cells
(see for example Refs. [18, 21, 22]); (3) the intracellular
and extracellular eﬀects of S100B are not univocal (as an
example, at micromolar concentrations extracellular S100B
cause astrocyte death via overproduction of NO [62]a n d
neuronalandmyoblastdeathviaoverproductionofROS[68,
70]; yet, at the submicromolar-micromolar concentrations
found within astrocytes and myoblasts S100B stimulates
migration and, to a lesser extent, proliferation [22], and
reduces diﬀerentiation via inhibition of MyoD expression
[12], respectively); and (4) synthetic compounds with ability
to block S100B activity such as arundic acid [38] and pen-
tamidine [19] might not discriminate between intracellular
and extracellular S100B. While further work is required for
having a complete picture of intracellular and extracellular
regulatory eﬀects of S100B, current studies of the protein
in physiological and pathological conditions are shedding
light on the variety of cellular functions in which S100B is
involved.
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